NASDAQ:SGEN - Seattle Genetics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $69.21 +0.03 (+0.04 %) (As of 04/22/2019 01:55 PM ET)Previous Close$69.18Today's Range$67.97 - $69.4752-Week Range$47.75 - $84.37Volume30,155 shsAverage Volume1.16 million shsMarket Capitalization$11.14 billionP/E RatioN/ADividend YieldN/ABeta2.3 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. In addition, the company develops Enfortumab vedotin, ADC composed of an anti-Nectin-4 monoclonal antibody to treat bladder cancer, and ovarian and lung cancers; Tucatinib, an oral tyrosine kinase inhibitor for HER2-positive metastatic breast cancer; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. Further, it develops early-stage clinical product candidates comprising ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SGN-CD48A; SEA-BCMA for patients with relapsed or refractory multiple myeloma; and SGN-2FF for patients with advanced solid tumors. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Progenics Pharmaceuticals Inc.; Unum Therapeutics, Inc.; Pieris Pharmaceuticals, Inc.; Pieris Pharmaceuticals AG; Takeda Pharmaceutical Company Limited; Astellas Pharma, Inc.; and Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington. Receive SGEN News and Ratings via Email Sign-up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGEN Previous Symbol CUSIP81257810 CIK1060736 Webwww.seattlegenetics.com Phone425-527-4000Debt Debt-to-Equity RatioN/A Current Ratio2.90 Quick Ratio2.67Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$654.70 million Price / Sales17.02 Cash FlowN/A Price / Cash FlowN/A Book Value$7.95 per share Price / Book8.71Profitability EPS (Most Recent Fiscal Year)($1.65) Net Income$-222,690,000.00 Net Margins-34.01% Return on Equity-19.33% Return on Assets-16.72%Miscellaneous Employees1,302 Outstanding Shares160,960,000Market Cap$11.14 billion Next Earnings Date4/25/2019 (Confirmed) OptionableOptionable Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions What is Seattle Genetics' stock symbol? Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN." How were Seattle Genetics' earnings last quarter? Seattle Genetics, Inc. (NASDAQ:SGEN) announced its earnings results on Thursday, February, 7th. The biotechnology company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.36. The biotechnology company had revenue of $174.50 million for the quarter, compared to the consensus estimate of $164.03 million. Seattle Genetics had a negative net margin of 34.01% and a negative return on equity of 19.33%. The firm's revenue for the quarter was up 34.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.41) EPS. View Seattle Genetics' Earnings History. When is Seattle Genetics' next earnings date? Seattle Genetics is scheduled to release their next quarterly earnings announcement on Thursday, April 25th 2019. View Earnings Estimates for Seattle Genetics. How can I listen to Seattle Genetics' earnings call? Seattle Genetics will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8772601479. What guidance has Seattle Genetics issued on next quarter's earnings? Seattle Genetics updated its FY 2019 earnings guidance on Thursday, February, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $790-840 million, compared to the consensus revenue estimate of $864.94 million. What price target have analysts set for SGEN? 14 equities research analysts have issued twelve-month target prices for Seattle Genetics' shares. Their predictions range from $50.00 to $101.00. On average, they anticipate Seattle Genetics' stock price to reach $81.5455 in the next year. This suggests a possible upside of 18.1% from the stock's current price. View Analyst Price Targets for Seattle Genetics. What is the consensus analysts' recommendation for Seattle Genetics? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seattle Genetics in the last year. There are currently 1 sell rating, 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seattle Genetics. What are Wall Street analysts saying about Seattle Genetics stock? Here are some recent quotes from research analysts about Seattle Genetics stock: 1. According to Zacks Investment Research, "Seattle Genetics' sole marketed drug, Adcetris, is performing well since its launch. Adcetris’ recent label expansion in frontline stage III/IV Hodgkin lymphoma and in frontline CD30-expressing peripheral T-cell lymphomas (PTCL) bodes well for the company. The company’s collaboration with Takeda for the global development and commercialization of Adcetris also holds promise. However, its heavy dependence solely on Adcetris for growth is a concern. The recent label expansion of Merck’s Keytruda and Bristol-Myers’ Opdivo in the lymphoma indication will increase competition. Though the company has multiple candidates in its pipeline, most are in early developmental stages, hence, any regulatory setback for Adcetris could hurt sales. Shares have outperformed the industry so far this year. Estimates have improved ahead of Q1 earnings. Seattle Genetics has a mixed record of earnings surprises in the recent quarters." (4/10/2019) 2. HC Wainwright analysts commented, "We reach a price target of $98 after adjusting new corporate tax rate, cash, and other program updates. The price target is based on a sum-of-parts NPV-DCF ($63.2 HL + $3.6 relapsed sALCL+ $11.2 frontline PTCL + $17.7 platform + $2.9 cash). Key risks to achievement of our target price include trial failures, safety issues, regulatory delays, competition, and dilutive financing. Seattle Genetics Inc. February 8, 2019 H.C. WAINWRIGHT & CO. EQUITY RESEARCH 2Seattle Genetics, Inc." (2/8/2019) 3. JPMorgan Chase & Co. analysts commented, "With SGEN’s recent strength (up ~50% over the last 3 mos), we’ve been asked frequently – what would we need to see from Adcetris to maintain this momentum? In our view, this question should be more than adequately answered following a big beat this quarter with Adcetris sales coming in at $122.4M vs guidance of $105-110M and consensus of $107M. Additionally, management provided 3Q guidance of $130-135M vs cons of $115M. Coupled with continued pipeline progress (completion of enrollment in the pivotal cohort of EV-201 and first patient dosed in innovaTV 204/207, as previously disclosed), as well as narrowing of guidance for E-2 (now early 4Q18) we see this as another productive quarter on many fronts." (7/27/2018) Has Seattle Genetics been receiving favorable news coverage? Media stories about SGEN stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Seattle Genetics earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. Who are some of Seattle Genetics' key competitors? Some companies that are related to Seattle Genetics include Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Qiagen (QGEN), bluebird bio (BLUE), BIO-TECHNE (TECH), Neurocrine Biosciences (NBIX), Spark Therapeutics (ONCE), China Biologic Products (CBPO), argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Repligen (RGEN), Denali Therapeutics (DNLI), Halozyme Therapeutics (HALO) and Acceleron Pharma (XLRN). What other stocks do shareholders of Seattle Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seattle Genetics investors own include Immunomedics (IMMU), Celgene (CELG), Gilead Sciences (GILD), Incyte (INCY), Heron Therapeutics (HRTX), Alexion Pharmaceuticals (ALXN), Starbucks (SBUX), ImmunoGen (IMGN), Micron Technology (MU) and Silvercorp Metals (SVM). Who are Seattle Genetics' key executives? Seattle Genetics' management team includes the folowing people: Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 58)Mr. Todd E. Simpson, Chief Financial Officer (Age 58)Dr. Vaughn B. Himes, Chief Technology Officer (Age 58)Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 51)Dr. Jonathan G. Drachman, Strategic Advisor for Innovation (Age 57) Who are Seattle Genetics' major shareholders? Seattle Genetics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Manning & Napier Group LLC (0.39%), Rhenman & Partners Asset Management AB (0.09%), Gateway Investment Advisers LLC (0.04%), Gulf International Bank UK Ltd (0.02%), Nisa Investment Advisors LLC (0.01%) and Virtu Financial LLC (0.01%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Clay B Siegall, Darren S Cline, David W Gryska, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics. Which major investors are selling Seattle Genetics stock? SGEN stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Rhenman & Partners Asset Management AB, D.B. Root & Company LLC, State of Alaska Department of Revenue and Nisa Investment Advisors LLC. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, Darren S Cline, David W Gryska, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics. Which major investors are buying Seattle Genetics stock? SGEN stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Meeder Asset Management Inc., Rothschild Investment Corp IL, Hollencrest Capital Management, Canton Hathaway LLC, Spectrum Management Group Inc., Flagship Harbor Advisors LLC and Gulf International Bank UK Ltd. View Insider Buying and Selling for Seattle Genetics. How do I buy shares of Seattle Genetics? Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Seattle Genetics' stock price today? One share of SGEN stock can currently be purchased for approximately $69.03. How big of a company is Seattle Genetics? Seattle Genetics has a market capitalization of $11.11 billion and generates $654.70 million in revenue each year. The biotechnology company earns $-222,690,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Seattle Genetics employs 1,302 workers across the globe. What is Seattle Genetics' official website? The official website for Seattle Genetics is http://www.seattlegenetics.com. How can I contact Seattle Genetics? Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected] MarketBeat Community Rating for Seattle Genetics (NASDAQ SGEN)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 528 (Vote Outperform)Underperform Votes: 554 (Vote Underperform)Total Votes: 1,082MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe SGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/22/2019 by MarketBeat.com StaffFeatured Article: What do investors mean by earnings per share?